Banu Lebe Selected Research

Proteins (Proteins, Gene)

3/2007	Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis.
3/2005	The clinical significance of p53, p21, and p27 expressions in rectal carcinoma.
1/2004	The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas.
1/2003	HMB45 and melan-A expression in renal angiomyolipoma and their significance for the diagnosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Banu Lebe Research Topics

Disease

4	Neoplasms (Cancer) 03/2007 - 01/2003
2	Melanoma (Melanoma, Malignant) 01/2015 - 06/2007
2	Dysplastic Nevus Syndrome (Dysplastic Nevus) 10/2008 - 06/2007
2	Pigmented Nevus (Melanocytic Nevus) 10/2008 - 06/2007
2	Carcinoma (Carcinomatosis) 03/2005 - 02/2005
2	Adenocarcinoma 03/2005 - 01/2004
1	Scleritis (Episcleritis) 02/2024
1	Hyperemia 02/2024
1	Cysts 02/2024
1	Pyoderma Gangrenosum 12/2023
1	Febrile Ulceronecrotic Mucha-Habermann disease 05/2023
1	COVID-19 11/2022
1	Lupus Erythematosus Panniculitis (Panniculitis, Lupus) 11/2022
1	B-Cell Lymphoma (Lymphoma, B Cell) 10/2021
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2021
1	Localized Scleroderma (Morphea) 01/2021
1	Kyrle disease 03/2020
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2017
1	Hepatocellular Carcinoma (Hepatoma) 08/2014
1	Necrobiosis Lipoidica 01/2013
1	Dermatitis 01/2012
1	Epidermolysis Bullosa 01/2012
1	Grover's disease 01/2012
1	Benign Familial Pemphigus (Hailey Hailey Disease) 01/2012
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2011
1	Lymphoma (Lymphomas) 09/2011
1	Cutaneous Malignant Melanoma 10/2008
1	Glomus Tumor (Glomus Tumors) 09/2008
1	Miliary Tuberculosis 05/2007
1	Churg-Strauss Syndrome (Allergic Angiitis) 05/2007
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2007
1	Lymphatic Metastasis 03/2007
1	Retinal Detachment (Retinal Detachments) 01/2007
1	Retinal Perforations 01/2007
1	Metaplasia 04/2005
1	Neoplasm Metastasis (Metastasis) 03/2005
1	Pleomorphic Adenoma 02/2005
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2004
1	Infections 04/2003
1	Angiomyolipoma 01/2003
1	Drug Eruptions (Drug Eruption) 09/2002
1	Neonatal hemochromatosis 09/2002

Drug/Important Bio-Agent (IBA)

4	Proteins (Proteins, Gene)FDA Link 03/2007 - 01/2003
3	Formaldehyde (Formol)FDA Link 06/2007 - 01/2004
3	ParaffinIBA 06/2007 - 01/2004
2	Cyclin D1IBA 06/2007 - 01/2004
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2024
1	secukinumabIBA 12/2023
1	Erythromycin (Erycette)FDA LinkGeneric 05/2023
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 05/2023
1	mRNA VaccinesIBA 11/2022
1	Retinaldehyde (Retinal)IBA 10/2021
1	ibrutinibIBA 01/2021
1	Antinuclear AntibodiesIBA 01/2017
1	InterferonsIBA 01/2015
1	Sorafenib (BAY 43-9006)FDA Link 08/2014
1	Immunoglobulin A (IgA)IBA 01/2012
1	Immunoglobulin M (IgM)IBA 09/2011
1	Collagen Type IV (Type IV Collagen)IBA 10/2008
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 09/2008
1	SteroidsIBA 05/2007
1	Prednisolone (Predate)FDA LinkGeneric 05/2007
1	SurvivinIBA 03/2007
1	densironIBA 01/2007
1	oxane HDIBA 01/2007
1	Hematoxylin (Haematoxylon)IBA 04/2005
1	Eosine Yellowish-(YS) (Eosin)IBA 04/2005
1	Alcian BlueIBA 04/2005
1	CyclinsIBA 01/2004
1	Cell Cycle ProteinsIBA 01/2004
1	Vitamin A (Retinol)FDA LinkGeneric 04/2003
1	Carotenoids (Carotene)IBA 04/2003
1	MART-1 AntigenIBA 01/2003
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 09/2002

Therapy/Procedure

1	Slit Lamp 02/2024
1	Transjugular Intrahepatic Portasystemic Shunt 03/2020
1	Therapeutics 01/2015
1	Bariatric Surgery 01/2013
1	Scleral Buckling 01/2007
1	Vitrectomy 01/2007
1	Endotamponade 01/2007
1	Radiotherapy 02/2005